30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AstraZeneca PLC trades at 63.7x earnings, 90% below its 5-year average of 652.8x, sitting at the 72nd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 169%. On a free-cash-flow basis, the stock trades at 27.5x P/FCF, 56% below the 5-year average of 62.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $323.2B | $548.3B | $406.4B | $420.0B | $425.0B | $330.6B | $265.2B | $262.8B | $186.0B | $163.6B | $136.4B |
| Enterprise Value | $347.1B | $572.3B | $431.0B | $442.8B | $448.0B | $355.0B | $277.8B | $275.7B | $200.3B | $178.1B | $148.2B |
| P/E Ratio → | 63.75 | 53.67 | 115.04 | 70.39 | 128.51 | 2896.25 | 82.79 | 194.23 | 86.35 | 54.25 | 39.04 |
| P/S Ratio | 5.50 | 9.33 | 7.52 | 9.17 | 9.58 | 8.84 | 9.96 | 10.78 | 8.42 | 7.28 | 5.93 |
| P/B Ratio | 13.37 | 11.25 | 9.94 | 10.72 | 11.47 | 8.42 | 16.96 | 18.01 | 13.24 | 9.83 | 8.18 |
| P/FCF | 27.47 | 46.60 | 55.86 | 63.96 | 58.73 | 87.86 | 120.94 | 516.31 | 149.15 | 83.55 | 74.49 |
| P/OCF | 21.27 | 36.09 | 34.26 | 40.60 | 43.33 | 55.45 | 55.27 | 88.52 | 71.04 | 45.72 | 32.91 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
AstraZeneca PLC's enterprise value stands at 17.8x EBITDA, 58% below its 5-year average of 42.1x. The Healthcare sector median is 13.8x, placing the stock at a 29% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.74 | 7.97 | 9.67 | 10.10 | 9.49 | 10.44 | 11.30 | 9.07 | 7.93 | 6.44 |
| EV / EBITDA | 17.82 | 29.38 | 28.60 | 33.73 | 49.72 | 68.82 | 34.47 | 41.23 | 28.05 | 26.53 | 20.41 |
| EV / EBIT | 25.26 | 40.60 | 41.55 | 52.17 | 116.94 | 351.13 | 53.54 | 93.44 | 59.62 | 49.65 | 30.13 |
| EV / FCF | — | 48.64 | 59.24 | 67.43 | 61.90 | 94.34 | 126.66 | 541.57 | 160.61 | 90.95 | 80.93 |
Margins and return-on-capital ratios measuring operating efficiency
AstraZeneca PLC earns an operating margin of 23.4%. Operating margins have expanded from 17.9% to 23.4% over the past 3 years, signaling improving operational efficiency. ROE of 22.9% indicates solid capital efficiency. ROIC of 14.9% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% |
| Operating Margin | 23.4% | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% |
| Net Profit Margin | 17.5% | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 22.9% | 17.6% | 15.6% | 8.6% | 0.4% | 21.1% | 9.3% | 14.0% | 18.0% | 19.9% |
| ROA | 9.4% | 9.4% | 6.9% | 6.0% | 3.3% | 0.1% | 5.0% | 2.2% | 3.5% | 4.8% | 5.7% |
| ROIC | 14.9% | 14.9% | 11.8% | 10.1% | 4.6% | 1.7% | 13.9% | 7.9% | 8.5% | 9.3% | 13.2% |
| ROCE | 17.2% | 17.2% | 13.6% | 11.6% | 4.9% | 1.6% | 11.5% | 6.7% | 7.4% | 7.8% | 10.6% |
Solvency and debt-coverage ratios — lower is generally safer
AstraZeneca PLC carries a Debt/EBITDA ratio of 1.5x, which is manageable (51% below the sector average of 3.1x). Net debt stands at $24.0B ($29.7B total debt minus $5.7B cash). Interest coverage of 8.1x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.61 | 0.74 | 0.73 | 0.79 | 0.78 | 1.30 | 1.25 | 1.36 | 1.07 | 1.01 |
| Debt / EBITDA | 1.53 | 1.53 | 2.00 | 2.18 | 3.23 | 5.95 | 2.53 | 2.73 | 2.68 | 2.65 | 2.32 |
| Net Debt / Equity | — | 0.49 | 0.60 | 0.58 | 0.62 | 0.62 | 0.80 | 0.88 | 1.02 | 0.87 | 0.71 |
| Net Debt / EBITDA | 1.23 | 1.23 | 1.63 | 1.74 | 2.55 | 4.72 | 1.56 | 1.92 | 2.00 | 2.16 | 1.62 |
| Debt / FCF | — | 2.04 | 3.39 | 3.47 | 3.17 | 6.47 | 5.72 | 25.26 | 11.45 | 7.40 | 6.44 |
| Interest Coverage | 8.11 | 8.11 | 5.95 | 5.16 | 2.82 | 0.83 | 4.06 | 2.09 | 2.48 | 2.70 | 3.59 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.94x is below 1.0, meaning current liabilities exceed current assets — though the company's $5.7B cash position helps mitigate short-term liquidity concerns. The current ratio has improved from 0.82x to 0.94x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | 0.94 | 0.93 | 0.82 | 0.86 | 1.16 | 0.96 | 0.86 | 0.96 | 0.80 | 0.87 |
| Quick Ratio | 0.72 | 0.72 | 0.74 | 0.64 | 0.68 | 0.76 | 0.76 | 0.68 | 0.78 | 0.62 | 0.72 |
| Cash Ratio | 0.19 | 0.19 | 0.20 | 0.19 | 0.24 | 0.28 | 0.39 | 0.34 | 0.35 | 0.28 | 0.39 |
| Asset Turnover | — | 0.51 | 0.52 | 0.45 | 0.46 | 0.36 | 0.40 | 0.40 | 0.36 | 0.35 | 0.37 |
| Inventory Turnover | 1.62 | 1.62 | 1.93 | 1.52 | 2.64 | 1.38 | 1.32 | 1.54 | 1.71 | 1.42 | 1.77 |
| Days Sales Outstanding | — | 94.31 | 75.84 | 66.98 | 75.65 | 79.33 | 77.49 | 73.29 | 49.49 | 45.53 | 40.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AstraZeneca PLC returns 1.0% to shareholders annually — split between a 0.8% dividend yield and 0.2% buyback yield. A payout ratio of 49.6% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 1.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.8% | 1.8% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.8% | 3.6% | 4.0% | 5.1% |
| Payout Ratio | 49.6% | 49.6% | 65.8% | 75.2% | 132.7% | 3442.9% | 111.8% | 269.1% | 161.7% | 117.3% | 101.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.6% | 1.9% | 0.9% | 1.4% | 0.8% | 0.0% | 1.2% | 0.5% | 1.2% | 1.8% | 2.6% |
| FCF Yield | 3.6% | 2.1% | 1.8% | 1.6% | 1.7% | 1.1% | 0.8% | 0.2% | 0.7% | 1.2% | 1.3% |
| Buyback Yield | 0.2% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.0% | 2.0% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.8% | 3.6% | 4.0% | 5.1% |
| Shares Outstanding | — | $3.1B | $3.1B | $3.1B | $3.1B | $2.9B | $2.6B | $2.6B | $2.5B | $2.5B | $2.5B |
Compare AZN with 3 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| AZNYou | $323B | 63.7 | 17.8 | 27.5 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| LLY | $942B | 89.9 | 50.5 | 2273.1 | 81.3% | 38.9% | 84.3% | 33.7% | 1.7 |
| JNJ | $599B | 42.9 | 20.7 | 30.2 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| BMY | $127B | -14.1 | 8.7 | 9.1 | 56.8% | 20.0% | -39.0% | 12.4% | 2.7 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how AZN stacks up against sector leader Eli Lilly and Company.
Start ComparisonAstraZeneca PLC's current P/E ratio is 63.7x. The historical average is 49.6x. This places it at the 72th percentile of its historical range.
AstraZeneca PLC's current EV/EBITDA is 17.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.4x.
AstraZeneca PLC's return on equity (ROE) is 22.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 24.1%.
Based on historical data, AstraZeneca PLC is trading at a P/E of 63.7x. This is at the 72th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
AstraZeneca PLC's current dividend yield is 0.78% with a payout ratio of 49.6%.
AstraZeneca PLC has 81.9% gross margin and 23.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
AstraZeneca PLC's Debt/EBITDA ratio is 1.5x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.